公开(公告)号：US20230339930A1

公开(公告)日：2023-10-26

申请号：US18004996

申请日：2021-07-07

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Qingyi Yang

IPC: C07D417/14 ,  A61P31/14

CPC classification number: C07D417/14 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I




wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US11684616B2

公开(公告)日：2023-06-27

申请号：US17246551

申请日：2021-04-30

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/444 ,  A61K45/06

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20220257563A1

公开(公告)日：2022-08-18

申请号：US17660270

申请日：2022-04-22

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: A61K31/403 ,  A61P31/14 ,  C07D403/12 ,  A61K31/427 ,  A61K31/401

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20200172539A1

公开(公告)日：2020-06-04

申请号：US16679820

申请日：2019-11-11

Applicant: Pfizer Inc.

Inventor： Rebecca Anne Gallego ,  Sajiv Krishnan Nair ,  Robert Steven Kania ,  Omar Khaled Ahmad ,  Ted William Johnson ,  Jamison Bryce Tuttle ,  Mehran Jalaie ,  Michele Ann McTigue ,  Dahui Zhou ,  Matthew L. Del Bel ,  Ru Zhou ,  Mingying He

IPC: C07D471/04 ,  A61P35/00

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US10590128B2

公开(公告)日：2020-03-17

申请号：US16069585

申请日：2017-01-09

Applicant: Pfizer Inc.

Inventor： Thomas Allen Chappie ,  Jaclyn Louise Henderson ,  Joseph Michael Young ,  Travis T. Wager ,  Bethany Lyn Kormos ,  Nandini Chaturbhai Patel ,  Simone Sciabola ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Joseph Walter Tucker

IPC: C07D471/04 ,  A61K31/55 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/22

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

公开(公告)号：US20190047997A1

公开(公告)日：2019-02-14

申请号：US16069585

申请日：2017-01-09

Applicant: Pfizer Inc.

Inventor： Thomas Allen Chappie ,  Jaclyn Louise Henderson ,  Joseph Michael Young ,  Travis T. Wager ,  Bethany Lyn Kormos ,  Nandini Chaturbhai Patel ,  Simone Sciabola ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Joseph Walter Tucker

IPC: C07D471/04

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.